{"id":191303,"date":"2024-06-16T16:22:28","date_gmt":"2024-06-16T21:22:28","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/06\/trial-of-tech-to-freeze-kidney-tumors-shows-it-is-safe-and-effective"},"modified":"2024-06-16T16:22:28","modified_gmt":"2024-06-16T21:22:28","slug":"trial-of-tech-to-freeze-kidney-tumors-shows-it-is-safe-and-effective","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/06\/trial-of-tech-to-freeze-kidney-tumors-shows-it-is-safe-and-effective","title":{"rendered":"Trial Of Tech To Freeze Kidney Tumors Shows It Is \u2018Safe And Effective\u2019"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/trial-of-tech-to-freeze-kidney-tumors-shows-it-is-safe-and-effective2.jpg\"><\/a><\/p>\n<p><a href=\"https:\/\/icecure-medical.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">IceCure Medical<\/a>, an Israeli company that developed a way to freeze and destroy tumors (cryoablation) as alternative to surgery, says an interim analysis of its current kidney cancer trial shows the platform is a safe and effective treatment for malignant renal tumors, with 89.5 percent recurrence-free rate.<\/p>\n<p>The data from the analysis for the trial of the ProSense platform was presented at the Annual Israeli Conference on Interventional Radiology in Tel Aviv on June 10.<\/p>\n<p>Cryoablation is not a new process, but IceCure\u2019s system allows physicians to perform the procedure at their own office, with no need for hospitalization. It also uses liquid nitrogen instead of a mixture of argon and helium gasses, which is cheaper, can be frozen faster, and is easier to maintain at sub-zero temperatures, shortening the treatment time.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>IceCure Medical, an Israeli company that developed a way to freeze and destroy tumors (cryoablation) as alternative to surgery, says an interim analysis of its current kidney cancer trial shows the platform is a safe and effective treatment for malignant renal tumors, with 89.5 percent recurrence-free rate. The data from the analysis for the trial [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-191303","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=191303"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/191303\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=191303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=191303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=191303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}